

Drug Policy

Policy:	201902-MRx (01-24)	Initial Effective Date: 02/22/2019
Code(s):	HCPCS J9210, C9050	Annual Review Date: 01/18/2024
SUBJECT:	Gamifant™ (emapalumab-lzsg)	Last Review Date: 01/18/2024

Subject to Site of Care

Prior approval is required for some or all procedure codes listed in this Corporate Drug Policy.

POLICY STATEMENT

This policy involves the use of Gamifant. Prior authorization is recommended for medical benefit coverage of Gamifant. Approval is recommended for those who meet the conditions of coverage in the **Initial Approval and Renewal Criteria, Preferred Drug (when applicable), Dosing/Administration, Length of Authorization, and Site of Care (when applicable)** for the diagnosis provided. The requirement that the patient meet the Criteria and Preferred Drug for coverage of the requested medication applies to the initial authorization only. All approvals for initial therapy are provided for the initial approval duration noted below; if reauthorization is allowed, a response to therapy is required for continuation of therapy.

I. Length of Authorization

Coverage will be provided for 6 months and may be renewed.

II. Dosing Limits

A. Quantity Limit (max daily dose) [NDC Unit]:

- Gamifant 10 mg/2 mL single-dose vial: 32 vials per 30 days (4 vials per dose)
- Gamifant 50 mg/10 mL single-dose vial: 8 vials per 30 days (1 vial per dose)
- Gamifant 100 mg/20 mL single-dose vial: 88 vials per 30 days (11 vials per dose)

B. Max Units (per dose and over time) [HCPCS Unit]:

- 2300 billable units weekly

III. Initial Approval Criteria ^{1,3-7}

Coverage is provided in the following conditions:

Universal Criteria

Drug Policy

- Patient has been evaluated and screened for the presence of latent tuberculosis (TB) infection prior to initiating treatment and will receive ongoing monitoring, every 2 weeks and as clinically indicated, for the presence of TB during treatment; **AND**
- Patient will receive prophylaxis for Herpes Zoster, *Pneumocystis Jirovecii*, and fungal infections; **AND**
- Patient does not have an active infection, including clinically important localized infections that are favored by interferon-gamma (e.g., infections caused by mycobacterium, *Histoplasma Capsulatum*, etc.); **AND**
- Must not be administered concurrently with live or live attenuated vaccines; **AND**
- Patient has NOT received hematopoietic stem cell transplant (HSCT)*; **AND**

Hemophagocytic Lymphohistiocytosis (HLH) † Φ

- Patient has a definitive diagnosis of HLH as indicated by the following:
 - Patient diagnosis of primary HLH based on identification of biallelic pathogenic gene variants from molecular genetic testing (e.g., *PRF1*, *UNC13D*, *STX11*, or *STXBP2*) or a family history consistent with primary HLH; **OR**
 - Patient has at least FIVE of the following eight documented criteria:
 - Prolonged fever (> 7 days)
 - Splenomegaly
 - Cytopenias affecting 2 of 3 lineages in the peripheral blood (hemoglobin < 9 g/dL, platelets < 100 x 10⁹/L, neutrophils < 1 x 10⁹/L)
 - Hypertriglyceridemia (fasting triglycerides > 3 mmol/L or ≥ 265 mg/dL) and/or hypofibrinogenemia (≤ 1.5 g/L)
 - Hemophagocytosis in bone marrow, spleen, or lymph nodes with no evidence of malignancy
 - Low or absent NK-cell activity
 - Ferritin ≥ 500 mcg/L
 - Soluble CD25 (aka soluble IL-2Rα receptor) ≥ 2400 U/mL; **AND**
- Patient has active, primary disease that is refractory, recurrent, or progressive during treatment with conventional ~~or were intolerant to of, conventional~~ HLH therapy (e.g., dexamethasone, etoposide, cyclosporine A, anti-thymocyte globulin, etc.) unless patient is intolerant to conventional HLH therapy; **AND**
- Used in combination with dexamethasone (*Note: Patients currently on oral cyclosporine A, or intrathecal methotrexate and/or glucocorticoids may continue on therapy while treated with emapalumab*)

† FDA Approved Indication(s); ‡ Compendium Recommended Indication(s); Φ Orphan Drug

Drug Policy

IV. Renewal Criteria ^{1,3-6}

Coverage can be renewed based on the following criteria:

- Patient continues to meet the universal and other indication-specific relevant criteria such as concomitant therapy requirements (not including prerequisite therapy), etc. identified in section III; **AND**
- Absence of unacceptable toxicity from the drug. Examples of unacceptable toxicity include: serious infections (including mycobacteria, Herpes Zoster virus, and Histoplasma Capsulatum), infusion-related reactions (including drug eruption, pyrexia, rash, erythema, and hyperhidrosis), etc.; **AND**
- Patient is receiving ongoing monitoring every 2 weeks for adenovirus, EBV, and CMV viruses and as clinically indicated; **AND**
- Patient continues to require therapy for treatment of HLH (ei.ge., until HSCT is performed or unacceptable toxicity); **AND**
- Patient experienced a disease improvement in HLH abnormalities as evidenced by one of the following:
 - Complete response defined as normalization of all HLH abnormalities (*i.e., no fever, no splenomegaly, neutrophils > 1x10⁹/L, platelets > 100x10⁹/L, ferritin < 2,000 µg/L, fibrinogen > 1.50 g/L, D-dimer < 500 µg/L, normal CNS symptoms, no worsening of sCD25 > 2-fold baseline*); **OR**
 - Partial response defined as normalization of ≥ 3 HLH abnormalities (including CNS abnormalities); **OR**
 - HLH improvement defined as ≥ 3 HLH abnormalities improvement ~~owed~~ by at least 50% from baseline of ≥ 3 HLH clinical and laboratory criteria (including CNS involvement); **OR**
- Dose escalation (up to the maximum dose and frequency specified below) requests based on clinical and laboratory parameters being interpreted as an unsatisfactory response are defined as at least ONE of the following:
 - Fever – persistence or recurrence
 - Platelet count
 - If baseline < 50,000/mm³ and no improvement to >50,000/mm³
 - If baseline > 50,000/mm³ and less than 30% improvement
 - If baseline > 100,000/mm³ and decrease to < 100,000/mm³
 - Neutrophil count
 - If baseline < 500/mm³ and no improvement to > 500/mm³
 - If baseline > 500 -1000/mm³ and decrease to < 500/mm³
 - If baseline 1000-1500/mm³ and decrease to < 1000/mm³
 - Ferritin (ng/mL)
 - If baseline ≥ 3000 ng/mL and < 20% decrease
 - If baseline < 3000 ng/mL and any increase to > 3000 ng/mL

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

- Splenomegaly – any worsening
- Coagulopathy (both D-dimer and fibrinogen must apply)
 - D-Dimer
 - If abnormal at baseline and no improvement
 - Fibrinogen (mg/dL)
 - If baseline levels ≤ 100 mg/dL and no improvement
 - If baseline levels > 100 mg/dL and any decrease to < 100 mg/dL

**Patients should be evaluated for HSCT when a high-risk of relapse and a high-risk of mortality exists (e.g., homozygous or compound heterozygous HLH mutations exists, lack of response to initial HLH therapy, central nervous system involvement, and incurable hematologic malignancy).*

V. Dosage/Administration ¹

Indication	Dose
HLH	Administer initial doses of 1 mg/kg, intravenously over one hour, twice <u>per week (every three to four days) weekly</u> . Titrate doses up to 10 mg/kg as follows: <ul style="list-style-type: none"> – On day 3, if an unsatisfactory improvement in clinical condition is assessed by the healthcare provider (<u>see criteria in section IV</u>), increase to 3 mg/kg. – From day 6 and onwards, if an unsatisfactory improvement in clinical condition is assessed by the healthcare provider on the 3 mg/kg dose, increase to 6 mg/kg. – From day 9 and onwards, if an unsatisfactory improvement in clinical condition is assessed by the healthcare provider on the 6 mg/kg dose, increase to 10 mg/kg.
<ul style="list-style-type: none"> – Used in combination with dexamethasone at a daily dose of at least 5-10 mg/m² starting the day before Gamifant treatment begins. – Administer until hematopoietic stem cell transplantation (HSCT) is performed or unacceptable toxicity. – Discontinue when a patient no longer requires therapy for the treatment of HLH. 	

VI. Billing Code/Availability Information

HCPCS Code:

- J9210 – Injection, emapalumab-lzsg, 1 mg; 1 billable unit = 1 mg

NDC:

- Gamifant 10 mg/2 mL single-dose vial: 66658-0501-xx
- Gamifant 50 mg/10 mL single-dose vial: 66658-0505-xx
- Gamifant 100 mg/20 mL single-dose vial: 66658-0510-xx

VII. References

1. Gamifant [package insert]. Waltham, MA; Sobi, Inc., May 2022. Accessed December 2023².

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

2. Jordan M, Locatelli F, Allen C, et al. A Novel Targeted Approach to the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) with an Anti-Interferon Gamma (IFN γ) Monoclonal Antibody (mAb), NI-0501: First Results from a Pilot Phase 2 Study in Children with Primary HLH. *Blood* 2015 126:LBA-3
3. Zhang K, Astigarraga I, Bryceson Y, et al. Familial Hemophagocytic Lymphohistiocytosis. 2006 Mar 22 [Updated 2021 Sept 30]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. *GeneReviews®* [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2022. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1444/>.
4. Jordan M, Allen C, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis. *Blood*. 2011;118(15):4041. Epub 2011 Aug 9.
5. Ouachée-Chardin M, Elie C, de Saint Basile G, et al. Hematopoietic stem cell transplantation in hemophagocytic lymphohistiocytosis: a single-center report of 48 patients. *Pediatrics*. 2006;117(4):e743.
6. McClain KL. Treatment and prognosis of hemophagocytic lymphohistiocytosis. In Newburger P (Ed), *UpToDate*. Last updated: May 6, 2022. Accessed on December 4⁸, 2023². Available from https://www.uptodate.com/contents/treatment-and-prognosis-of-hemophagocytic-lymphohistiocytosis?search=Treatment%20and%20prognosis%20of%20hemophagocytic%20lymphohistiocytosis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
7. NovoImmune SA. A Study to Investigate the Safety and Efficacy of an Anti-IFN γ mAb in Children Affected by Primary Haemophagocytic Lymphohistiocytosis. Available from: <https://clinicaltrials.gov/ct2/show/NCT01818492?term=01818492&draw=1&rank=1>. ClinicalTrials.gov Identifier: NCT01818492. Accessed December 2023².
8. Locatelli F, Jordan MB, Allen C, et al. Emapalumab in Children with Primary Hemophagocytic Lymphohistiocytosis. *N Engl J Med*. 2020 May 7;382(19):1811-1822. doi: 10.1056/NEJMoa1911326.

Appendix 1 – Covered Diagnosis Codes

ICD-10	ICD-10 Description
D76.1	Hemophagocytic lymphohistiocytosis

Appendix 2 – Centers for Medicare and Medicaid Services (CMS)

[The preceding information is intended for non-Medicare coverage determinations. Medicare coverage for outpatient \(Part B\) drugs is outlined in the Medicare Benefit Policy Manual \(Pub. 100-2\), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determinations \(NCDs\) and/or Local Coverage Determinations \(LCDs\) may exist and compliance with these policies is required where applicable. Local Coverage Articles \(LCAs\) may also exist for claims payment purposes or to clarify benefit eligibility under Part B for drugs which may be self-administered. The following link may be used to search for NCD, LCD, or LCA documents: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications, including any preceding information, may be applied at the discretion of the](#)

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

health plan Medicare coverage for outpatient (Part B) drugs is outlined in the Medicare Benefit Policy Manual (Pub. 100-2), Chapter 15, §50 Drugs and Biologicals. In addition, National Coverage Determination (NCD), Local Coverage Articles (LCAs) and Local Coverage Determinations (LCDs) may exist and compliance with these policies is required where applicable. They can be found at: <https://www.cms.gov/medicare-coverage-database/search.aspx>. Additional indications may be covered at the discretion of the health plan.

Medicare Part B Covered Diagnosis Codes (applicable to existing NCD/LCA/LCD): N/A

Medicare Part B Administrative Contractor (MAC) Jurisdictions		
Jurisdiction	Applicable State/US Territory	Contractor
E (1)	CA, HI, NV, AS, GU, CNMI	Noridian Healthcare Solutions, LLC
F (2 & 3)	AK, WA, OR, ID, ND, SD, MT, WY, UT,	Noridian Healthcare Solutions, LLC
5	KS, NE, IA, MO	Wisconsin Physicians Service Insurance Corp (WPS)
6	MN, WI, IL	National Government Services, Inc. (NGS)
H (4 & 7)	LA, AR, MS, TX, OK, CO, NM	Novitas Solutions, Inc.
8	MI, IN	Wisconsin Physicians Service Insurance Corp (WPS)
N (9)	FL, PR, VI	First Coast Service Options, Inc.
J (10)	TN, GA, AL	Palmetto GBA, LLC
M (11)	NC, SC, WV, VA (excluding below)	Palmetto GBA, LLC
L (12)	DE, MD, PA, NJ, DC (includes Arlington & Fairfax counties and the city of Alexandria in	Novitas Solutions, Inc.
K (13 & 14)	NY, CT, MA, RI, VT, ME, NH	National Government Services, Inc. (NGS)
15	KY, OH	CGS Administrators, LLC

Documentation Requirements:

The Company reserves the right to request additional documentation as part of its coverage determination process. The Company may deny reimbursement when it has determined that the drug provided or services performed were not medically necessary, investigational or experimental, not within the scope of benefits afforded to the member and/or a pattern of billing or other practice has been found to be either inappropriate or excessive. Additional documentation supporting medical necessity for the services provided must be made available upon request to the Company. Documentation requested may include patient records, test results and/or credentials of the provider ordering or

This document is subject to the disclaimer found at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> and is subject to change. Always verify with the most current version at <https://www.medmutual.com/For-Providers/Policies-and-Standards/CorporateMedicalDisclaimer.aspx> or <https://www.medmutual.com/For-Providers/Policies-and-Standards/Prescription-Drug-Resources.aspx>

Drug Policy

performing a service. The Company also reserves the right to modify, revise, change, apply and interpret this policy at its sole discretion, and the exercise of this discretion shall be final and binding.

FOR MEDICAL BENEFIT COVERAGE REQUESTS:

Prior approval is required for HCPCS Code J9210 and C9050